Galapagos (GB:0JXZ)
LSE:0JXZ
0JXZ Stock Chart & Stats
€24.30
€0.10(0.38%)
At close: 4:00 PM EST
€24.30
€0.10(0.38%)
Day’s Range― - ―
52-Week Range€20.74 - €32.70
Previous CloseN/A
Volume42.14K
Average Volume (3M)9.16K
Market Cap
€1.61B
Enterprise Value€1.53B
Total Cash (Recent Filing)€3.00B
Total Debt (Recent Filing)€12.10M
Price to Earnings (P/E)5.7
Beta0.63
Next Earnings
May 06, 2026EPS Estimate
-0.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)11.87
Shares Outstanding65,897,070
10 Day Avg. Volume4,733
30 Day Avg. Volume9,162
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.57
Price to Sales (P/S)1.66
P/FCF Ratio-8.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€25.85Price Target Upside6.38% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering4
EPS Forecast (FY)-2.08
Revenue Forecast (FY)€81.19M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetVery low net debt versus large equity provides durable financial flexibility. This conservatism reduces refinancing and covenant risk, supports continued R&D spending or opportunistic M&A/partnerships, and gives the company runway to execute long-term clinical programs without immediate liquidity stress.
Profitability Rebound (2024-2025)A material earnings recovery and strong 2025 top-line show the business can generate sustained operating profitability. Durable profitability improves internal funding capacity, enhances credit standing for longer-term projects, and can support reinvestment into pipeline advancement and commercialization capabilities.
Diversified Biotech Revenue ModelA hybrid model of collaboration/licensing plus retained product sales provides multiple durable cash levers: upfronts, milestones and royalties as well as territory sales. This diversification reduces dependence on any single product launch and helps monetize R&D progress across development stages.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow is a structural risk: it forces reliance on cash reserves or external funding to cover operations and R&D. Over months this can compress strategic optionality, raise dilution risk if equity is issued, and increase vulnerability to capital market cycles.
Shrinking Asset BaseDeclining total assets may reflect reduced investments, asset sales, or amortization, potentially lowering long-term productive capacity. Over time a smaller asset base can constrain growth, reduce collateral for borrowing, and signal that past investments are not being replaced at the pace required for sustained expansion.
Earnings Volatility / Non‑recurring RevenueHistoric swings between losses and gains and dependence on milestone-driven or one-off items create lumpy, unpredictable earnings. This undermines the predictability of cash flows and makes long-term planning, R&D budgeting, and investor confidence more challenging than for firms with steadier recurring revenues.
Galapagos News
0JXZ FAQ
What was Galapagos’s price range in the past 12 months?
Galapagos lowest share price was €20.74 and its highest was €32.70 in the past 12 months.
What is Galapagos’s market cap?
Galapagos’s market cap is €1.61B.
When is Galapagos’s upcoming earnings report date?
Galapagos’s upcoming earnings report date is May 06, 2026 which is in 25 days.
How were Galapagos’s earnings last quarter?
Galapagos released its earnings results on Feb 23, 2026. The company reported €11.87 earnings per share for the quarter, beating the consensus estimate of -€0.11 by €11.98.
Is Galapagos overvalued?
According to Wall Street analysts Galapagos’s price is currently Undervalued.
Does Galapagos pay dividends?
Galapagos does not currently pay dividends.
What is Galapagos’s EPS estimate?
Galapagos’s EPS estimate is -0.82.
How many shares outstanding does Galapagos have?
Galapagos has 65,897,070 shares outstanding.
What happened to Galapagos’s price movement after its last earnings report?
Galapagos reported an EPS of €11.87 in its last earnings report, beating expectations of -€0.11. Following the earnings report the stock price went up 5.934%.
Which hedge fund is a major shareholder of Galapagos?
Currently, no hedge funds are holding shares in GB:0JXZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Galapagos
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
0JXZ Stock 12 Month Forecast
Average Price Target
€25.85
▲(6.38% Upside)
Technical Analysis
Options Prices
Currently, No data available
---